非小细胞肺癌患者应用益气通络解毒方配合EGFR-TKI靶向治疗的疗效及对患者生存质量的影响.docVIP

非小细胞肺癌患者应用益气通络解毒方配合EGFR-TKI靶向治疗的疗效及对患者生存质量的影响 梁继珍 易基群 广州市红十字会医院暨南大学医学院附属广州红十字会医院肿瘤科 X 关注成功！ 加关注后您将方便地在 我的关注中得到本文献的被引频次变化的通知！ 新浪微博 腾讯微博 人人网 开心网 豆瓣网 网易微博 摘????要： 目的:探讨应用益气通络解毒方配合EGFR-TKI (包括吉非替尼和厄洛替尼) 靶向对非小细胞肺癌患者的治疗效果以及对患者生存质量的影响。方法:选择50例非小细胞肺癌患者为研究对象, 将其随机分为观察组和对照组。观察组采用益气通络解毒方联合EGFR-TKI治疗的方法, 对照组采用EGFR-TK进行治疗。观察两组患者经过治疗后生活质量评价、治疗疗效 (临床有效率) 以及不良反应的评价。结果:观察组临床疗效高于对照组, 其治疗的疗效更加明显, 差异具有统计学的意义 (P0.05) 。而两组患者的不良反应方面, 主要是皮疹和轻度腹泻两方面, 其差异无统计学意义 (P0.05) , 表明两种方式安全度都比较高。生活质量的改善方面, 观察组患者的生活质量改善程度优于对照组, 差异有统计学意义 (P0.05) 。结论:在对非小细胞肺癌患者的治疗中应用益气通络解毒方配合EGFR-TKI靶向能够对其临床病症起到有效的缓解作用, 对患者的生存质量有较大程度上的改善, 并且比较安全, 是治疗非小细胞肺癌的有效方式, 应该在临床中加以应用。 关键词： 非小细胞肺癌; 益气通络解毒方; EGFR-TKI; 生存质量; 收稿日期：2017-09-04 Effect of Yiqi Tongluo Jiedu Decoction Combined with EGFR-TKI Targeted Therapy on Patients with Non-small Cell Lung Cancer and Its Effect on Patients Quality of Life LIANG Ji-zhen YI Ji-qun Department of Oncology, Guangzhou Red Cross Hospital and Guangzhou Red Cross Hospital Affiliated to Jinan University Medical College; Abstract： Objective To explore the application of Yiqitongluo decoction combined with EGFR-TKI (including gefitinib and erlotinib) targeting patients of non-small cell lung cancer treatment effect and the influence on the quality of life of patients. Method 50 patients with non-small cell lung cancer treated in our hospital from April 2014 to August-2016 were randomly divided into the observation group and the control group. The observation group was treated with Yiqi Tongluo Jiedu decoction combined with EGFR-TKI, while the control group was treated with EGFR-TK. The quality of life, treatment efficacy (clinical efficiency) and adverse reactions were evaluated in two groups after treatment. Results the clinical curative effect of the observation group was higher than that of the control group, and the curative effect of the observation group was more obvious, the difference was statistically significant (P 0. 05) . The two groups of patients with adverse reactions